New York: US pharmaceutical giant Pfizer said today it was abandoning plans for a USD 160 billion merger
with Allergan, citing new US rules cracking down on tie ups aimed at saving on taxes.
Pfizer said in a statement the two companies "terminated by mutual agreement" plans to merge.
"Pfizer approached this transaction from a position of strength and viewed the potential combination as an accelerator of existing strategies," said company chairman and CEO Ian Read.
Pfizer also agreed to pay Allergan USD 150 million to reimburse its expenses linked to the planned merger. The decision to call off the merger came after the US Treasury Department announced new rules to discourage mergers between US and foreign businesses designed to sharply lower the US company's tax bill.
The New York-based pharmaceutical giant said it remains on track to report its 2016 first quarter earnings on May 3. For all of 2015, Pfizer reported earnings of USD 7.7 billion, down 15.2 per cent from 2014. Revenues dipped 1.5 per cent to USD 48.9 billion.
Allergan CEO Brent Saunders said in a separate statement that while he is "disappointed" that the merger will not proceed, his company is nevertheless "poised to deliver strong, sustainable growth built on a set of powerful attributes."
Published Date: Apr 06, 2016 06:59 pm | Updated Date: Apr 06, 2016 06:59 pm